Leflunomide Aurobindo (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By limiting pyrimidine production, the drug suppresses the proliferation of activated T‑lymphocytes, thereby dampening the autoimmune response that drives inflammation in arthritic diseases.

The specific dose of leflunomide is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Physicians typically start with a loading dose followed by a maintenance dose, but the exact regimen should be confirmed with the prescriber.

Leflunomide is classified as pregnancy category X because it is known to cause fetal malformations. It is contraindicated in pregnancy, and women of child‑bearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Leflunomide and methotrexate are both conventional DMARDs, but they differ in mechanism and safety profile. Leflunomide targets pyrimidine synthesis, whereas methotrexate inhibits folate metabolism. Leflunomide may be preferred when methotrexate is poorly tolerated, but it carries a higher risk of liver toxicity and teratogenicity, requiring careful monitoring.

Leflunomide Aurobindo should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight. Keep the container tightly closed and out of reach of children.

Leflunomide Aurobindo is taken orally, usually as a tablet swallowed whole with water. It is typically administered once daily, but the exact schedule and any dose adjustments must be directed by the prescribing healthcare professional.

The most serious risks include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, bone‑marrow suppression leading to pancytopenia, interstitial lung disease, and teratogenic effects. Patients should report symptoms like jaundice, unexplained bruising, persistent cough or rash to their physician promptly.

Leflunomide is contraindicated in pregnant women, patients with severe liver disease, uncontrolled hypertension, active infections, or known hypersensitivity to the drug. It should also be avoided in individuals planning pregnancy without effective contraception and in those with a history of severe skin reactions.